Lucentis implant nears clinic
This article was originally published in Scrip
Executive Summary
Genentech (Roche) has decided to file an IND application for clinical testing of an implantable ocular device designed to provide sustained delivery of Lucentis (ranibizumab).
You may also be interested in...
Regeneron's Extended Eylea Dosing Plan Suffers US FDA Delay
Competitors are moving forward on wet AMD products with longer dosing intervals, with Novartis close to filing with FDA.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.